Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,361
Completed, industry sponsors, Hematology and blood cancers, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting286
- Completed1,361
1,361 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT03386513 · 179 participants · Start Jan 2, 2018 · Primary completion Oct 2, 2024
Drug: IMGN632 · For: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 18 sites in all
GPCR Therapeutics, Inc.Industry
NCT05561751 · 28 participants · Start Feb 13, 2023 · Primary completion Sep 30, 2025
Drug: GPC-100; Propranolol and 1 more · For: Multiple Myeloma
Sites: La Jolla, California; Gainesville, Florida; Indianapolis, Indiana · 10 sites in all
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT06978699 · 26 participants · Start May 21, 2025 · Primary completion Jan 21, 2026
Drug: XH-S003 Capsule; XH-S003 Capsule and 1 more · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02568267 · 534 participants · Start Nov 19, 2015 · Primary completion Oct 29, 2026
Drug: Entrectinib · For: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer and 13 more
Sites: Phoenix, Arizona; Duarte, California; La Jolla, California · 115 sites in all
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT05459571 · 35 participants · Start Aug 9, 2022 · Primary completion Nov 24, 2025
Drug: Axicabtagene Ciloleucel; Cyclophosphamide and 2 more · For: Relapsed or Refractory Large B-cell Lymphoma
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 16 sites in all
Halia Therapeutics, Inc.Industry
NCT07052006 · 37 participants · Start Dec 9, 2023 · Primary completion Jan 8, 2026
Drug: HT-6184 · For: Myelodysplastic Syndrome; Anemia in Myelodysplastic Syndromes
Sites: Ahmedabad, India; Kannur, India; Visakhapatnam, India · 10 sites in all
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
Cothera Bioscience, IncIndustry
NCT05263583 · 14 participants · Start Dec 3, 2022 · Primary completion Feb 12, 2025
Drug: Sepantronium Bromide · For: High-grade B-cell Lymphoma; Burkitt Lymphoma; Lymphoma, B-Cell and 6 more
Sites: Beijing, China; Guangzhou, China; Henan, China · 11 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03533283 · 211 participants · Start May 8, 2018 · Primary completion Oct 22, 2026
Drug: Glofitamab; Atezolizumab and 4 more · For: Non-Hodgkins Lymphoma
Sites: Charlotte, North Carolina; Ghent, Belgium; Aarhus N, Denmark · 20 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04875195 · 66 participants · Start Jun 7, 2021 · Primary completion Dec 14, 2023
Drug: Pembrolizumab · For: Hodgkin's Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Sites: Torrance, California; New Orleans, Louisiana; Annapolis, Maryland · 27 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT07446491 · 54 participants · Start Jun 6, 2025 · Primary completion Oct 10, 2026
Drug: PN20; Placebo · For: Thrombocytopenia Associated With Chronic Liver Disease
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 8 sites in all
AbbVieAbbVie (ABBV)
NCT05105841 · 20 participants · Start Nov 8, 2021 · Primary completion Oct 9, 2025
Drug: Venetoclax; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Sites: Nagoya, Japan; Chiba, Japan; Matsuyama, Japan · 20 sites in all
Evopoint Biosciences Inc.Industry
NCT06558513 · 120 participants · Start Aug 3, 2021 · Primary completion Aug 30, 2025
Drug: XNW5004 tablets · For: Advanced Tumor; Lymphoma
Sites: Tianjin, China
Blueprint Medicines CorporationIndustry
NCT03580655 · 107 participants · Start Nov 21, 2018 · Primary completion Dec 18, 2024
Drug: Avapritinib · For: Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematologic Neoplasm and 1 more
Sites: Stanford, California; Chicago, Illinois; Westwood, Kansas · 32 sites in all
Werewolf Therapeutics, Inc.Industry
NCT06939283 · 24 participants · Start Apr 21, 2025 · Primary completion Apr 23, 2026
Drug: WTX-330 · For: Advanced or Metastatic Solid Tumors; Non-Hodgkin Lymphoma
Sites: Scottsdale, Arizona; Atlanta, Georgia; Chicago, Illinois · 5 sites in all
PfizerPfizer (PFE)
NCT04649359 · 187 participants · Start Feb 2, 2021 · Primary completion Jun 17, 2022
Drug: Elranatamab (PF-06863135) · For: Multiple Myeloma
Sites: Beverly Hills, California; Irvine, California; Los Angeles, California · 78 sites in all
Otsuka Beijing Research InstituteOtsuka
NCT04233346 · 93 participants · Start Jul 9, 2020 · Primary completion Jul 22, 2022
Drug: Ponatinib 30mg OD; Ponatinib 45mg OD · For: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Sites: Hefei, China; Guangzhou, China; Wuhan, China · 14 sites in all
- Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyCompleted
GCP-Service International West GmbHIndustry
NCT05583552 · 46 participants · Start Jun 5, 2023 · Primary completion Mar 27, 2025
Drug: Imetelstat sodium · For: Myelodysplastic Syndromes; Acute Myeloid Leukemia
Sites: Adelaide, Australia; Brisbane, Australia; Nedlands, Australia · 11 sites in all
Incyte CorporationIncyte (INCY)
NCT04455841 · 84 participants · Start Mar 19, 2021 · Primary completion Apr 1, 2025
Drug: INCB000928; ruxolitinib · For: Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
Sites: Duarte, California; Irvine, California; Los Angeles, California · 34 sites in all
Alaunos TherapeuticsIndustry
NCT00423644 · 17 participants · Start Jan 2007 · Primary completion Dec 21, 2007
Drug: Darinaparson · For: Multiple Myeloma
Sites: Glendale, Arizona; Santa Barbara, California; Santa Rosa, California · 8 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT01414855 · 100 participants · Start Aug 31, 2011 · Primary completion Dec 31, 2013
Drug: obinutuzumab; cyclophosphamide and 3 more · For: Lymphoma, B-Cell
Sites: Birmingham, Alabama; Encinitas, California; Aurora, Colorado · 38 sites in all
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.Completed
PfizerPfizer (PFE)
NCT05228470 · 39 participants · Start Dec 21, 2021 · Primary completion Aug 6, 2023
Drug: Elranatamab · For: Elranatamab; Myeloma; Multiple Myeloma and 8 more
Sites: Fuzhou, China; Guangzhou, China; Shenzhen, China · 15 sites in all
- Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03974113 · 32 participants · Start Jan 28, 2020 · Primary completion Aug 4, 2026
Drug: Fitusiran · For: Hemophilia
Sites: Los Angeles, California; Hackensack, New Jersey; Cleveland, Ohio · 16 sites in all
HutchmedIndustry
NCT06601504 · 61 participants · Start Nov 5, 2024 · Primary completion May 23, 2026
Drug: HMPL-760 planned dose 1; R-GemOx and 3 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Fuzhou, China; Guangzhou, China; Nanning, China · 16 sites in all
Elixiron Immunotherapeutics Inc.Industry
NCT06745583 · 7 participants · Start Dec 16, 2024 · Primary completion Mar 6, 2026
Drug: EI-1071 tablet, oral · For: Mild, Moderate, or Severe Alzheimer's Disease
Sites: Taipei, Taiwan · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.